Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can help compared to other options. For more information, visit: http://www.cancertypeid.com
Author: Editor
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses clinical trials of new treatments for Hodgkin lymphoma (HL). Topics of interest include bendamustine-containing regimen (BeGEV) as induction chemotherapy prior to autologous stem cell transplantation for patients with relapsed or refractory HL and the phase 1 trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for elderly patients with HL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients with multiple myeloma. Prof Lonial focuses on the basic and clinical aspects of several novel monoclonal antibodies, including daratumumab, which targets CD38, and elotuzumab, which targets signalling lymphocytic activation molecule-F7 (SLAMF7). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Kidney Test
Dr. Geo Espinosa of NYU Langone Medical Center talks about the holistic approach in patient care in Integrative Urology which combines traditional therapies and complementary medicine for maximum patient benefit.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer Index (BCI) and its impact on patient confidence in their treatment plan. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the randomised controlled phase 2 Borealis-1 trial, which evaluated the efficacy and safety of gemcitabine and cisplatin with and without apatorsen, a novel antisense oligonucleotide that inhibits heat shock protein 27 (Hsp27) production, in patients with metastatic bladder cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX, discusses the ongoing PERSIST-2 trial, which is a multicentre, randomised phase 3 trial comparing the efficacy and safety of pacritinib versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, provides an overview of promising novel immunotherapeutic strategies that are currently under investigation for the treatment of patients with kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, London, UK, discusses the results of the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase 1b trial that evaluated the safety and efficacy of the PI3K? inhibitor, idelalisib, in combination with chemoimmunotherapy for patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Investigated combinations include idelalisib in combination with rituximab; ofatumumab; bendamustine and rituximab; fludarabine; and chlorambucil. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North Carolina, Chapel Hill, NC, discusses the results of the double-blind, phase 3 PALOMA-3 trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood to test for acquired resistance is easier and quicker than needle biopsies. How long until it is standard practice in the US?
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses a multicentre phase 2 study, which is evaluating brentuximab vedotin plus adriamycin, vinblastine and dacarbazine (AVD) for patients with non-bulky limited-stage Hodgkin lymphoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 3 ELOQUENT-2 trial of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory multiple myeloma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, summarises the concept of precision medicine in cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune responses and clinical outcomes in STAND, a randomised phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in men with biochemically recurrent prostate cancer after local therapy failure. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL, explains the current landscape and unmet clinical needs in geriatric oncology. Older patients have highly variable physiologic ages, so there is an increasing emphasis on individualising treatment to optimise clinical outcomes. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Naples, Italy, discusses the median progression-free survival (PFS) evaluation and correlative biomarker analysis from coBRIM, a phase 3 study of cobimetinib plus vemurafenib in patients with advanced BRAF-mutated melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, discusses the increasing focus on physiological factors in preference to chronological age in determining optimal treatment decisions in older patients with breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of a phase 2/3 trial, which evaluated if maintenance therapy with lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, after first-line chemotherapy is associated with clinical benefit in patients with HER1/2-positive metastatic transitional cell carcinoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0 to 100. This number indicates the likelihood that a woman’s breast cancer will spread to another area of her body within 10 years of her initial diagnosis. The lower the score is, the lower the chances are that the woman’s breast cancer will come back. The higher the score is, the greater the chances that the breast cancer will come back. Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses how the Recurrence…
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer Index (BCI) in treatment decision making. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. For more information, visit: http://www.cancertypeid.com
At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea, MBBS, BSc, PhD, FRCP, of the University of Birmingham, Birmingham, United Kingdom, UK, discuss the molecular diversity of breast cancer. They explain that patients with breast cancer can be categorised using molecular tools to help guide clinical decision-making. Focusing on giving clinicians practical advice for the consultation room, they review the results of the Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey, which evaluated patient attributes and clinician attitudes considered for decision-making with regard to adjuvant chemotherapy in early…
Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase 3 trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma. NIVO combined with IPI and NIVO alone had superior clinical activity versus IPI alone. The results with NIVO combined with IPI and NIVO alone further suggest complementary activity of the two agents. There were no new safety signals or drug-related deaths observed with the combination. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa in patients with localised high-risk prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast Cancer Assay and how it is performed, detailing the specificities of the test and how the Recurrence Score® result is reported. She highlights how her multidisciplinary team chooses to use a genomic test, such as the Oncotype DX assay, to guide adjuvant chemotherapy decisions in luminal breast cancers. She comments on the use of the Oncotype DX assay with traditional markers and other markers such as ER, PR or HER2. The Recurrence Score result is complementary for select patients. Her…
Anne Armstrong, MRCP, PhD, MB ChB, BSc(Hons), of The Christie Hospital, Manchester, UK, and Nigel Bundred, MD, FRCS, of The University of Manchester, UK, discuss genomic profiling for patients with breast cancer and the Oncotype DX® Breast Cancer Assay. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the recommended treatment approach for oestrogen receptor (ER)-positive, HER2-negative breast cancer patients. Prof Rugo comments on the expected benefit of adjuvant chemotherapy and endocrine therapy in luminal breast cancers and mentions that one of the greatest challenges is to understand the heterogeneity of the tumour. She also comments on the use of criteria, such as tumour grade and size, to select patients for adjuvant chemotherapy as well as the usage of immunohistochemistry (IHC) markers, such as hormone receptor markers, to identify…
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For more information, visit: http://www.cancertypeid.com
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses the results of the double-blind, phase 3 PALOMA3 trial of fulvestrant with or without the novel cyclin-dependent kinase 4/6 inhibitor, palbociclib, in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who progressed on prior endocrine therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the recent progress in understanding clinically relevant genomic alterations in kidney cancer. Genomic profiling of collecting duct carcinomas, a rare kidney cancer subtype, revealed a high frequency of NF2 genomic alterations, which may represent opportunities for the application of targeted therapies. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the recent development of molecularly targeted therapies in the management of haematological malignancies. Emerging targeted agents include monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), elotuzumab, for multiple myeloma; anti-CD38 mAb, daratumumab, for multiple myeloma; anti-CD20 mAb, obinutuzumab, for chronic lymphocytic leukaemia (CLL); and ibrutinib plus bendamustine for CLL. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on new treatments for patients with multiple myeloma. Topics of interest include chimeric antigen receptor (CAR) T-cell therapy, the anti-CS1 humanised monoclonal antibody, elotuzumab, lenalidomide maintenance therapy, first-line treatment of newly diagnosed multiple myeloma using lenalidomide plus dexamethasone, and the histone deacetylase (HDAC) inhibitor, panobinostat. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, Omaha, NE, describes ASCO’s initiatives for the upcoming year. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer Index (BCI) to assist in determining whether to extend the adjuvant therapy of women with breast cancer beyond 5 years. For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets for therapy. For more information, visit: http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif, France, reviews the results of the phase 3 CheckMate 067 trial of nivolumab in treatment-naive patients with advanced melanoma, and the phase 3 COMBI-d trial, which compared the combination of dabrafenib and trametinib versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Jacqueline Barrientos, MD, summarises recent progress in the treatment of chronic lymphocytic leukaemia at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. He highlights trials on combined BRAF and MEK inhibition versus BRAF inhibition alone, and immunotherapy drug combinations. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the phase 3 CheckMate 067 trial of nivolumab alone or combined with ipilimumab versus ipilimumab alone in treatment-naive patients with advanced melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University of Sydney, Sydney, Australia, discusses the results of the randomised, double-blinded, phase 3 COMBI-d trial, which compared the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) versus dabrafenib and placebo as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center, New York, NY, discusses the results of the randomised phase 3 NCCTG N0574 (Alliance) trial of whole brain radiation therapy in addition to stereotactic radiosurgery in patients with 1 to 3 brain metastases. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, provides an overview of the current unmet needs in the treatment of metastatic kidney cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews